Momordica charantia L., a typical vegetable with multiple medicinal properties, is widely culti-vated around the world.
Anti-diabetic, anti-obesity, anti-cancer, anti-microbial, hypotensive, antioxidant, anti-hyperlipidemic, anti-inflammatory, immunomodulatory, anthelmintic, and protective properties have been well clarified both in vitro and in vivo, which might be due to various phytochemicals, such as carbohydrates, protein, fatty acids, amino acids, phenolic acids, minerals, essential oils, alkaloids, vitamins, flavonoids, and triterpenoids.
This review summarizes the active components and medicinal properties of different parts of M. charantia, especially the anti-diabetic and anti-cancer properties, aiming to highlight the medicinal usage of M. charantia and provide valuable references for the development of M. charantia as multifunctional food and medicine.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Lucas EA, Dumancas G, Smith B, Arjmandi BH. Health benefits of bitter melon (Momordica charantia). Bioactive Foods in Promoting Health. 2010;35:525–49.
Wang SZ, Li ZL, Yang GL, Ho CT, Li SM. Momordica charantia: a popular health-promoting vegetable with multifunctionality. Food Funct. 2017;8(5):1749–62.
Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm. 2003;65:356–9.
Tan HF, Gan CY. Polysaccharide with antioxidant, α-amylase inhibitory and ace inhibitory activities from Momordica charantia. Int J Biol Macromol. 2016;85:487–96.
Li ZJ, Chen JC, Deng YY, Song NL, Yu MY, Zhou L, et al. Two new cucurbitane triterpenoids from immature fruits of Momordica charantia. Helv Chim Acta. 2015;98(10):1456–61.
Krawinkel MB, Keding GB. Bitter gourd (Momordica charantia): a dietary approach to hyperglycemia. Nutr Rev. 2010;64(7):331–7.
Talapatra S, Ghoshal N, Raychaudhuri SS. Molecular characterization, modeling and expression analysis of a somatic embryogenesis receptor kinase (serk) gene in Momordica charantia L. during somatic embryogenesis. Plant cell Tiss. Org. 2014;116(3):271–83.
Lo HY, Li CC, Ho TY, Hsiang CY. Identification of the bioactive and consensus peptide motif from Momordica charantia insulin receptor-binding protein. Food Chem. 2016;204:298–305.
Guan L. Synthesis and anti-tumour activities of sulphated polysaccharide obtained from Momordica charantia. Nat Prod Res. 2012;26(14):1303–9.
Panda BC, Mondal S, Devi K, Sanjana P. Pectic polysaccharide from the green fruits of Momordica charantia (Karela): structural characterization and study of immunoenhancing and antioxidant properties. Carbohydr Res. 2015;401:24–31.
Deng YY, Yi Y, Zhang LF. Immunomodulatory activity and partial characterisation of polysaccharides from Momordica charantia. Molecules. 2014;19:13432–47.
Raish M, Ahmad A, Ansari MA, Alkharfy KM, Aljenobi FI, Jan BL, et al. Momordica charantia, polysaccharides ameliorate oxidative stress, inflammation, and apoptosis in ethanol-induced gastritis in mucosa through nf-kb signaling pathway inhibition. Int J Biol Macromol. 2018;111:193–9.
Popovich DG, Li L, Zhang W. Bitter melon (Momordica charantia) triterpenoid extract reduces preadipocyte viability, lipid accumulation and adiponectin expression in 3t3-l1 cells. Food Chem Toxicol. 2010;48(6):1619–26.
Murakami T, Emoto A, Matsuda H, Yoshikawa M. Medicinal foodstuffs. XXI. Structures of new cucurbitane-type triterpene glycosides, goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h, and new oleanane-type triterpene saponins, goyasaponins I, II, and III, from the fresh fruit of Japanese Momordica charantia L. Chem Pharm Bull (Tokyo) 2001; 49(1): 54–63.
Nakamura S, Murakami T, Nakamura J, Kobayashi H, Matsuda H, Yoshikawa M. Structures of new cucurbitane-type triterpenes and glycosides, karavilagenins and karavilosides, from the dried fruit of Momordica charantia L. in Sri lanka. Chem. Pharm. Bull. 2006;54(11):1545–50.
Mala A, Tulika T. Therapeutic efficacy of Centella asiatica (L.) and Momordica charantia: as traditional medicinal plant. J. Plant Sci. 2015;3(1–1):1–9.
Chen JC, Liu WQ, Lu L, Qiu MH, Zheng YT, Yang LM, et al. Kuguacins F-S, cucurbitane triterpenoids from Momordica charantia. Phytochemistry. 2009;70(1):133–40.
Chen J, Tian R, Qiu M, Lu L, Zheng Y, Zhang Z. Trinorcucurbitane and cucurbitane triterpenoids from the roots of Momordica charantia. Phytochemistry. 2008;69(4):1043–8.
Wu SB, Yue GG, To MH, Keller AC, Lau CB, Kennelly EJ. Transport in caco-2 cell monolayers of antidiabetic cucurbitane triterpenoids from Momordica charantia fruits. Planta Med. 2014;80(11):907–11.
Horax R, Hettiarachchy N, Islam S. Total phenolic contents and phenolic acid constituents in 4 varieties of bitter melons (Momordica charantia) and antioxidant activities of their extracts. J Food Sci. 2005;70:275–80.
Grossmann ME, Mizuno NK, Dammen ML, Schuster T, Ray A, Cleary MP. Eleostearic acid inhibits breast cancer proliferation by means of an oxidation-dependent mechanism. Cancer Prev Res. 2009;2(10):879–86.
Cummings E, Hundal HS, Wackerhage H, Hope M, Belle M, Adeghate E, et al. Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. Mol Cell Biochem. 2004;261(1):99–104.
Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20(5):649–88.
Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507–14.
Grover JK, Yadav SP. Pharmacological actions and potential uses of Momordica charantia : a review. J Ethnopharmacol. 2004;93(1):123–32.
Ahmed I, Adeghate E, Sharma AK, Pallot DJ, Singh J. Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes res clin Pr. 1998;40(3):145–51.
Xiang L, Huang X, Chen L, Rao P, Ke L. The reparative effects of Momordica charantia Linn. extract on HIT-T15 pancreatic beta-cells. Asia Pac. J Clin Nutr 2007; 16(1): 249–252.
Tripathi UN, Chandra D. Anti-hyperglycemic and anti-oxidative effect of aqueous extract of Momordica charantia pulp and Trigonella foenum graecum seed in alloxan-induced diabetic rats. Indian J Biochem Biophys. 2010;47(4):227–33.
Fernandes NP, Lagishetty CV, Panda VS, Naik SR. An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC Complem Altern M. 2007;7(1):1–8.
Shetty AK, Kumar GS, Sambaiah K, Salimath PV. Effect of bitter gourd (Momordica charantia) on glycaemic status in streptozotocin induced diabetic rats. Plant Food Hum Nutr. 2005;60(3):109–12.
Aljohi A, Matou-Nasri S, Liu D, Al-Khafaji N, Slevin M, Ahmed N. Momordica charantia extracts protect against inhibition of endothelial angiogenesis by advanced glycation endproducts in vitro. Food Funct. 2018;9(11):1–13.
Hsieh CH, Chen GC, Chen PH, Wu TF, Chao PM. Altered white adipose tissue protein profile in c57bl/6j mice displaying delipidative, inflammatory, and browning characteristics after bitter melon seed oil treatment. PLoS One. 2013;8(9):e72917.
Chuang CY, Hsu C, Chao CY, Wein YS, Kuo YH, Huang CJ. Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARα in bitter gourd (Momordica charantia L.). J Biomed Sci. 2006;13(6):763–72.
Yibchok-Anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S, Hsu WH. Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull. 2006;29(6):1126–31.
Platel K, Srinivasan K. Plant foods in the management of diabetes mellitus: vegetables as potential hypoglycaemic agents. Nahrung. 1997;41:68–74.
Chao CY, Huang CJ. Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acylCoA oxidase gene in H4IIEC3 hepatoma cells. J Biomed Sci. 2003;10:782–91.
Cheng HL, Huang HK, Chang CI, Tsai CP, Chou CH. A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate amp-activated protein kinase. J Agric Food Chem. 2008;56(16):6835–43.
Chaturvedi P, George S. Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load. J Med Food. 2010;13(3):520–7.
Wu SJ, Ng LT. Antioxidant and radical scavenging activities of wild bitter melon (Momordica charantia Linn.var.abbreviata Ser.) in Taiwan. LWT-food Sci. Technol. 2008;41:323–30.
Padmashree A, Sharma GK, Semwal AD, Bawa AS. Studies on the antioxygenic activity of bitter gourd (Momordica charantia) and its fractions using various in vitro models. J Sci Food Agric. 2011;91(4):776–82.
Kavitha CN, Babu SM, Rao MB. Influence of Momordica charantia on oxidative stress-induced perturbations in brain monoamines and plasma corticosterone in albino rats. Indian J Pharm. 2011;43(4):424–8.
Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res. 2010;70(5):1925–31.
Pitchakarn P, Suzuki S, Ogawa K, Pompimon W, Takahashi S, Asamoto M, et al. Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf. Cancer Lett. 2011;306(2):142–50.
Kwatra D, Subramaniam D, Ramamoorthy P, Standing D, Moran E, Velayutham R, et al. Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. Evid-Based Compl Al Med. 2013;1:221–9.
Fang EF, Zhang CZY, Fong WP, Ng TB. RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis. 2012;17(4):377–87.
Xiong SD, Kang Y, Liu XH, Li HY, Kirschenbaum A, Shen Y, et al. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer. 2009;125(4):774–82.
Brennan VC, Wang CM, Yang WH. Bitter melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, and insulin-like growth factor type 1 receptor/RAC-α serine/threonine-protein kinase signaling. J Med Food. 2012;15(4):325–34.
Rajamoorthi A, Shrivastava S, Steele R, Nerurkar P, Gonzalez JG, Crawford S, et al. Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-met signaling. PLoS One. 2013;8(10):e78006.
Fan Z, Lin L, Xie J. A mini-review of chemical and biological properties of polysaccharides from Momordica charantia. Int J Biol Macromol. 2016;92:246–53.
Braca A, Siciliano T, D’Arrigo M, Germanò MP. Chemical composition and antimicrobial activity of Momordica charantia seed essential oil. Fitoterapia. 2008;79(2):123–5.
Wu JD, Chen HM. Study on seperation, purification and biological activity for soluble polysaccharide from Momordica charantia. Food Sci. 2006;27(3):82–6.
Wang SZ, Zhang YB, Liu HG, He Y, Yan JJ, Wu ZH, et al. Molecular cloning and functional analysis of a recombinant ribosome-inactivating protein (alpha-momorcharin) from Momordica charantia. Appl Microbiol Biotechnol. 2012;96(4):939–50.
Akihisa T, Higo N, Tokuda H, Ukiya M, Akazawa H, Tochigi Y, Kimura Y, Suzuki T, Nishino H. Cucurbitane-type triterpenoids from the fruits of Momordica charantia and their cancer chemopreventive effects. J Nat Prod 2007; 70(8): 1233–1239.
Beloin N, Gbeassor M, Akpagana K, Hudson J, Soussa KD, Koumaglo K, et al. Ethnomedicinal uses of Momordica charantia, (Cucurbitaceae) in togo and relation to its phytochemistry and biological activity. J Ethnopharmacol. 2005;96(1–2):49–55.
Gürbüz İ, Akyüz C, Yeşilada E, Şener B. Anti-ulcerogenic effect of Momordica charantia L. fruits on various ulcer models in rats. J. Ethnopharmacol. 2000;71(1–2):77–82.
Telang MA, Pyati P, Sainani M, Gupta VS, Giri AP. Momordica charantia, trypsin inhibitor II inhibits growth and development of helicoverpa armigera. Insect Sci. 2009;16(5):371–80.
Ike K, Uchida Y, Nakamura T, Imai S. Induction of interferon-gamma (IFN-γ) and T helper 1 (Th1) immune response by bitter gourd extract. J Vet Med Sci. 2005;67(5):521–4.
Kobori M, Ohnishi-Kameyama M, Akimoto Y, Yukizaki C, Yoshida M. Alpha-eleostearic acid and its dihydroxy derivative are major apoptosis-inducing components of bitter gourd. J Agric Food Chem. 2008;56(22):10515–20.
Manabe M, Takenaka R, Nakasa T, Okinaka O. Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd). Biosci. Biotech. Bioch. 2003; 67(12): 2512–2517.
Yang WS, Yang E, Kim MJ, Jeong D, Yoon DH, Sung GH, et al. Momordica charantia inhibits inflammatory responses in murine macrophages via suppression of tak1. Am J Chinese Med. 2018;46(2):1.
Chan LL, Chen Q, Go AG, Lam EK, Li ET. Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J Nutr. 2005;135:2517–23.
Nerurkar PV, Johns LM, Buesa LM, Kipyakwai G, Volper E, Sato R, et al. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation. 2011;8(23):1–19.
Ng TB, Wong CM, Li WW, Yeung HW. A steryl glycoside fraction from Momordica charantia seeds with an inhibitory action on lipid metabolism in vitro. Biochem Cell Biol. 1986;4(8):766–71.
Chen Q, Li ET. Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. Brit J Nutr. 2005;93(5):747–54.
This work was supported by research grants from Huanggang Normal University (2014022203) and Foreign Cooperation Project of Hubei Science and Technology Department (2014BHE036).
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal sunjects performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Cancer Chemoprevention
About this article
Cite this article
Li, Z., Xia, A., Li, S. et al. The Pharmacological Properties and Therapeutic Use of Bitter Melon (Momordica charantia L.). Curr Pharmacol Rep 6, 103–109 (2020). https://doi.org/10.1007/s40495-020-00219-4
- Momordica charantia L.
- Traditional medicine
- Therapeutic use
- Pharmacological properties
- Therapeutic use